Negotiable: Paramount Recruitment: A brilliant new opportunity has just become available for a Bioinformatics Software Engineer to join a world leading Genetic Testing company, based in the UK. Frome, England

Negotiable: Paramount Recruitment: Bioinformatics Project Manager London Paramount are working in partnership with Genomics England to expand their team in order to deliver success Paramount are working in partnership with Genomics England to expand their team in order to with the 100,000 London, England

Negotiable: Paramount Recruitment: *Contribute to in-house pipeline to analyse WGS data of patients and aid in the interpretation of findings using clinical bioinformatics capabilities *Perform quality assurance of the analysis and interpretation made by third parties and by our in-house London, England

Notice NOT-OD-18-159 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-162 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-732 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support research on a) novel stigma reduction interventions that link to increase in care-seeking behavior and/or decrease in transmission; b) reducing the impact of stigma on adolescent and/or youth health; c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections; d) reducing effects of stigma on and/or by family members or caregivers of PLWH; and e) innovative and improved stigma measurement in the context of implementation of an intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to initiate exploratory studies to determine the feasibility of stigma interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).

Funding Opportunity PAR-18-727 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote research on food specific molecular signatures and biomarkers of dietary consumption and to promote collaborative interactions among NIH and USDA supported nutrition researchers.

Masters, PhD, or equivalent experience in a quantitative field (computer science, physics, mathematics, statistics, engineering, bioinformatics, etc.)....
From Atavas, Inc - Thu, 29 Mar 2018 05:00:57 GMT - View all Neenah, WI jobs

Candidates should submit a cover letter explaining specific interest in the position and prior research experience....
From Fred Hutchinson Cancer Research Center - Wed, 28 Mar 2018 22:38:11 GMT - View all Seattle, WA jobs

Funding Opportunity RFA-DA-19-006 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs in the use of ABCD data. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Research Experience involving cooperative and competitive use of ABCD datas

Funding Opportunity PA-18-729 from the NIH Guide for Grants and Contracts. IC reissue of FOA in response to the new clinical trial requirements. This funding opportunity announcement (FOA) calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex.

Funding Opportunity PA-18-728 from the NIH Guide for Grants and Contracts. IC reissue of FOA in response to the new clinical trial requirements. This funding opportunity announcement (FOA) calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex.

Funding Opportunity PA-18-718 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support high risk and high reward basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials.

Funding Opportunity PA-18-719 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials.

Our Lab is seeking outstanding and open minded Postdoctoral Fellows to work on developing and implementing cutting edge analysis to investigate the roles of T...
From Fred Hutchinson Cancer Research Center - Wed, 28 Mar 2018 16:38:07 GMT - View all Seattle, WA jobs

Funding Opportunity PAR-18-721 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental translational research (R21). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics to mitigate the health effects of chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The scope of the research includes basic toxicological research on the chemical threat for the purpose of target and therapeutic hit identification, hit validation, lead optimization, and demonstration of in vivo ADME/Tox and efficacy. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement programs or other related initiatives.

Funding Opportunity RFA-GM-18-003 from the NIH Guide for Grants and Contracts. The Coordination Center for the Models of Infectious Disease Agent Study (MIDAS) program will serve as a hub for collaboration, testing and dissemination of research products from the network of MIDAS investigators. The Coordination Center will also serve as the primary repository for MIDAS related datasets, models and software. The Coordination Center will maintain, promote and maximize utility and use of the shared MIDAS resources. In addition, the Program Director(s)/Principal Investigator(s) of the Coordination Center will proactively develop collaborative activities and training opportunities intended to enhance the utility of MIDAS resources and to improve the training experiences for members of the MIDAS network and their graduate students and postdoctoral researchers. Limited funding will also be provided to allow the Coordination Center to conduct impactful research on the evaluation and meta-analysis of existing modeling resources for the study of infectious disease spread and intervention.

Funding Opportunity PAR-18-726 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions to propose creative and innovative institutional research career development programs which prepare clinically-trained vision scientists for independent research careers. This initiative is intended to expand and strengthen the community of investigators engaged in clinical research. Such an increase in the number of well-trained clinical researchers is necessary to achieve a pool of scientists with contemporary, multidisciplinary expertise able to leverage recent advances in ocular genetics, therapeutics, bioengineering, and bio-behavioral research in order to enhance patient treatment and to increase scientific momentum in these fields. This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing a separate ancillary study to an existing trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. Applications supported by this FOA that meet the NIH definition of a clinical trial (see NOT-OD-15-015) must also fulfill the NIH requirements for either a mechanistic or minimal risk trial. A mechanistic trial is designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. A minimal risk trial is one in which the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. A proposed research career development program that includes a clinical trial that is not a mechanistic trial and/or involves a level of risk beyond that defined as minimal, will not be supported. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the

Funding Opportunity RFA-FD-18-016 from the NIH Guide for Grants and Contracts. The FDA Center for Drug Evaluation and Research (CDER) is encouraging applications to explore the development of HL7 Fast Healthcare Interoperability Resources (FHIR) standards to address healthcare and clinical research information exchange.

Funding Opportunity PA-18-724 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.